Article Details
Retrieved on: 2024-11-06 18:17:27
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA clearance of HuidaGene's CRISPR/Cas13 RNA-editing therapy, HG202, targeting neovascular age-related macular degeneration (AMD). This development connects biotechnology, genetic engineering, and gene therapy advancements, linking closely with AMD, CRISPR, and Editas Medicine within the scope of medical genetics.
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here